Recent News

• 05.29.2025 - Eledon leading a paradigm shift in immunosuppression therapy in organ transplantation
• 05.14.2025 - Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
• 04.30.2025 - CHLA Team Is First in World to Investigate Cardiac Xenotransplant as a ‘Bridge’ for Babies
• 04.07.2025 - David-Alexandre Gros, MD, on the Work to Bring Porcine Kidney Transplant to the Clinic
• 03.28.2025 - Gene Editing, Next-Gen Antibodies Key to Unlocking Animal-to-Human Transplants
• 03.20.2025 - Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
• 03.11.2025 - Leerink Partners Global Healthcare Conference
• 03.05.2025 - David-Alexandre Gros, MD, on Addressing Unmet Needs in End Stage Kidney Disease With Genetically Modified Porcine Kidney Transplant

Recent Filings

• 05.14.2025 - 8-K Current report
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2025 - EX-99.1 EX-99.1
• 04.29.2025 - DEF 14A Other definitive proxy statements
• 04.29.2025 - ARS Annual Report to Security Holders
• 04.29.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.14.2025 - 8-K/A Current report
• 04.14.2025 - PRE 14A Other preliminary proxy statements
• 04.07.2025 - 8-K Current report
• 03.20.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]